Medicine Matters rheumatology

Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.

Marwan Bukhari talks about the rationale behind investigating baricitinib and other JAK inhibitors for the treatment of COVID-19 and outlines the current efficacy data.

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19.

In this episode, Alfred (Al) Kim, a rheumatologist from the Washington University School of Medicine in St Louis, Missouri, USA, talks about hydroxychloroquine. He discusses why the drug was initially considered promising but later shown to be ineffective, and describes the impact drug shortages have had on rheumatology practice.

Find more on Medicine Matters rheumatology

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19.

For the introductory podcast, Jinoos Yazdany, rheumatologist and Professor of Medicine at the University of California, San Francisco in the USA, talks about the rationale behind investigating these agents and the role of rheumatologists in ensuring they are studied as safely and efficiently as possible.

Find more on Medicine Matters rheumatology

In April 2020, the American College of Rheumatology issued guidance for the management of people with rheumatic diseases during the COVID-19 pandemic.

We spoke to lead author Ted Mikuls, from the University of Nebraska Medical Center in the USA, to find out more about what rheumatologists should do to best care for their patients in light of COVID-19, and what some of the unanswered questions are.

Find more on Medicine Matters rheumatology

Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

Philip Robinson, chair of the steering committee for the COVID-19 Global Rheumatology Alliance, tells us about the initiative that will enable rheumatologists to document their patient experiences of COVID-19 and contribute to a shared learning resource (17:28).

Find more on Medicine Matters rheumatology

Image credit: COVID-19 illustration © koto_feja/Getty Images/iStock

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practice.

Find more on Medicine Matters rheumatology

Kevin Winthrop, from Oregon Health & Science University in Portland, USA, discusses why patients with rheumatic diseases may be vulnerable to COVID-19 and how different treatments may affect the risk for infection and prognosis of the disease.

Find more on Medicine Matters rheumatology

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

Listen to part 1 here

Find more on Medicine Matters rheumatology

Lead investigator Philip Mease outlines the results of the DISCOVER-2 trial, and discusses how guselkumab may impact the psoriatic arthritis treatment landscape.

Find more on Medicine Matters rheumatology

More from the 2019 ACR/ARP Annual Meeting

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.

Find more on Medicine Matters rheumatology

Image credits: © tashatuvango/Fotolia

Lead investigator Philip Mease discusses the findings from the SPIRIT-H2H trial, a phase III head-to-head trial of ixekizumab versus adalimumab in patients with psoriatic arthritis.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 15, 2019.

Lead investigator Philip Mease outlines the results of a phase IIb trial supporting further development of the anti-interleukin-23p19 monoclonal antibody tildrakizumab for the treatment of psoriatic arthritis.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on June 12, 2019.

In this podcast, we talk to Dana DiRenzo about the benefits of physical activity in patients with rheumatic diseases, as well as tools and strategies to enable patients to be more active.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on May 13, 2019.

Antonis Fanouriakis, lead author of the updated EULAR guidelines for the management of lupus, talks to medwireNews about what’s new in these guidelines and how they will influence clinical practice.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on May 7, 2019.

Dana DiRenzo discusses the impact of rheumatic diseases on mental health, and treatments and tools that are available to help support patients with these conditions.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on April 24, 2019.

In this Medicine Matters rheumatology podcast, Editorial Board member Victoria Ruffing discusses the impact that musculoskeletal diseases can have on work, and the various recommendations and resources that can help patients to remain in the workplace.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on February 1, 2019.

In this Medicine Matters rheumatology podcast, Editorial Board member Victoria Ruffing discusses the causes of sleep problems in patients with rheumatic diseases, the impact these may have on symptoms and quality of life, and strategies to help patients manage their sleep.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on January 4, 2019.

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on December 19, 2018.

In this medwireNews podcast, we talk to Editorial Board member Sangeeta Sule about how patients with juvenile arthritis transition from pediatric to adult care, the challenges associated with this transition, and how the process can be improved.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on July 13, 2018.

In this medwireNews podcast, Athimalaipet Ramanan outlines the importance of the SHARE recommendations for children with JIA-associated uveitis, and discusses how rheumatologists and ophthalmologists can work together.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on May 9, 2018.

In this medwireNews podcast, Editorial Board member Victoria Ruffing discusses how to talk to patients about biosimilar drugs, and outlines questions and concerns they may have.

Find more on Medicine Matters rheumatology http://bit.ly/Ruffing-Biosimilar-drugs

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on March 27, 2018.

Study investigator Jennifer Stinson discusses a trial assessing an online program to help teenagers with juvenile idiopathic arthritis to manage their condition.

Find more on Medicine Matters rheumatology

This content was originally published on Medicine Matters rheumatology (https://rheumatology.medicinematters.com/) on November 9, 2017.